Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab PK/PD in Healthy Chinese Volunteers
NCT03086356Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idarucizumab, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Measured Concentration of Idarucizumab in Plasma, Area Under the Effect Curve for Diluted Thrombin Time at Day 11 and 2 more. Started May 2017; status: completed.
02
Drugs
idarucizumab
Beyond the preview
Go deeper on NCT03086356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086356.